

**23 August 2011**

# **Acrux (ASX: ACR)**

## **2010/2011 Financial Results**

# FORWARD-LOOKING STATEMENTS

This presentation includes forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks and important factors that may cause the actual results, performance or achievements of Acrux to be materially different from the statements in this presentation.

Actual results could differ materially depending on factors such as the availability of resources, the results of clinical studies, the timing and effects of regulatory actions, the strength of competition and the effectiveness of patent protection.

## 2010/11 FINANCIAL RESULTS

- Profit after tax \$57.1 million +22% (2010: \$46.6 million)
- Earnings per share 35 cents +21% (2010: 29 cents)
- Revenue \$93.5 million +67% (2010: \$56.1 million)
- 60 cents per share special dividend paid in April 2011
- Cash reserves \$33 million
- Strong initial uptake of Axiron® in the US market
  - 22.3% of New to Brand Prescriptions
  - 6.1% of Total Prescriptions

# OUTLOOK

- Recuvyra® EMEA approval (Europe) - Q2 2011/12
- Recuvyra FDA decision (US) – Q3 2011/12
- Estradiol distribution partner – Q2 2011/12
- Axilla patent update – Q2 2011/12
- Axiron revenue:
  - 2011/12: US\$7 – 8 million
  - 2012/13: approx. US\$40 million
- Next dividend anticipated August 2012